Patents by Inventor Xiwei Wu
Xiwei Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230227913Abstract: The current disclosure provides, inter alia, method of determining benign nodules from thyroid cancer in a subject that is found to have a thyroid nodule, method of treating thyroid cancer in a subject detected to have thyroid cancer by the method of the current disclosure, compositions for determining benign nodules from thyroid cancer in a subject, and kits including reagents and composition for determining benign nodules from thyroid cancer in a subject.Type: ApplicationFiled: July 20, 2022Publication date: July 20, 2023Inventors: Maria A. Hahn, John H. Yim, Yuman Fong, Arthur X. Li, Xiwei Wu
-
Patent number: 11505829Abstract: The current disclosure provides, inter alia, method of determining benign nodules from thyroid cancer in a subject that is found to have a thyroid nodule, method of treating thyroid cancer in a subject detected to have thyroid cancer by the method of the current disclosure, compositions for determining benign nodules from thyroid cancer in a subject, and kits including reagents and composition for determining benign nodules from thyroid cancer in a subject.Type: GrantFiled: July 22, 2016Date of Patent: November 22, 2022Assignee: City of HopeInventors: Maria A. Hahn, John H. Yim, Yuman Fong, Arthur X. Li, Xiwei Wu
-
Publication number: 20220349012Abstract: The present subject matter provides, inter alia, a method of diagnosing invasive ductal cancer or detecting invasive ductal cancer risk in a subject who has ductal carcinoma in situ, a method of treating breast cancer in a subject detected to have invasive ductal cancer or determined to be at risk of invasive ductal cancer, compositions for detecting invasive presence or potential in ductal carcinoma in situ in a subject, and kits including reagents and composition for detecting invasive presence or potential in ductal carcinoma in situ in a subject.Type: ApplicationFiled: December 23, 2021Publication date: November 3, 2022Inventors: Maria A. Hahn, John H. Yim, Yuman Fong, Arthur X. Li, Xiwei Wu, Sun-Wing T.R. Tong
-
Patent number: 11242568Abstract: The present subject matter provides, inter alia, a method of diagnosing invasive ductal cancer or detecting invasive ductal cancer risk in a subject who has ductal carcinoma in situ, a method of treating breast cancer in a subject detected to have invasive ductal cancer or determined to be at risk of invasive ductal cancer, compositions for detecting invasive presence or potential in ductal carcinoma in situ in a subject, and kits including reagents and composition for detecting invasive presence or potential in ductal carcinoma in situ in a subject.Type: GrantFiled: December 28, 2018Date of Patent: February 8, 2022Assignee: City of HopeInventors: Maria A. Hahn, John H. Yim, Yuman Fong, Arthur X. Li, Xiwei Wu, Sun-Wing T. R. Tong
-
Patent number: 10793913Abstract: Provided are methods of treating breast cancer in a subject in need thereof comprising administering to the subject an effective amount of an inhibitor of miR-105 or an inhibitor of miR-122 are provided. Also provided herein are methods of determining a level of miR-105 or a level of miR-122 in a subject that has or is at risk for developing breast cancer. The method includes obtaining a biological sample from the subject and determining a level of miR-105 or a level of miR-122 or a combination thereof in the biological sample, wherein a higher level of miR-105 or miR-122 as compared to a control indicates that the subject has or is at risk of developing breast cancer.Type: GrantFiled: March 10, 2014Date of Patent: October 6, 2020Assignee: City of HopeInventors: Shizhen Emily Wang, Xiwei Wu
-
Patent number: 10457994Abstract: An miRNA expression signature comprising a set of one or more miRNAs associated with metastatic cancer is provided. In one embodiment, the expression signature is selected from the group consisting of miR-10b, miR-139-5p, miR-130b and miR-199b-5p. In some aspects, miR-199b-5p and miR-130b are overexpressed in metastatic cancer; and miR-10b and miR-139-5p are downregulated in metastatic cancer. Such an expression signature may be used in methods for predicting metastasis, risk for developing metastasis or a prognosis in a cancer. In another embodiment, a method for establishing such a cancer miRNA expression signature is provided.Type: GrantFiled: September 12, 2017Date of Patent: October 29, 2019Assignee: CITY OF HOPEInventors: Huiqing Wu, Xiwei Wu
-
Publication number: 20190284633Abstract: The present subject matter provides, inter alia, a method of diagnosing invasive ductal cancer or detecting invasive ductal cancer risk in a subject who has ductal carcinoma in situ, a method of treating breast cancer in a subject detected to have invasive ductal cancer or determined to be at risk of invasive ductal cancer, compositions for detecting invasive presence or potential in ductal carcinoma in situ in a subject, and kits including reagents and composition for detecting invasive presence or potential in ductal carcinoma in situ in a subject.Type: ApplicationFiled: December 28, 2018Publication date: September 19, 2019Applicant: City of HopeInventors: Maria A. Hahn, John H. Yim, Yuman Fong, Arthur X. Li, Ms, Xiwei Wu, Sun-Wing T.R. Tong
-
Publication number: 20180223370Abstract: An miRNA expression signature comprising a set of one or more miRNAs associated with metastatic cancer is provided. In one embodiment, the expression signature is selected from the group consisting of miR-10b, miR-139-5p, miR-130b and miR-199b-5p. In some aspects, miR-199b-5p and miR-130b are overexpressed in metastatic cancer; and miR-10b and miR-139-5p are downregulated in metastatic cancer. Such an expression signature may be used in methods for predicting metastasis, risk for developing metastasis or a prognosis in a cancer. In another embodiment, a method for establishing such a cancer miRNA expression signature is provided.Type: ApplicationFiled: September 12, 2017Publication date: August 9, 2018Inventors: Huiqing Wu, Xiwei Wu
-
Patent number: 9802949Abstract: Provided are fused tricyclic compounds effective to inhibit the function of the NS5A protein of formula (I), wherein X, X?, Y, Y?, A, A?, Q1, Q2, R1-R4, X4, R5a, f and W are defined as in the description. Also provided herein are pharmaceutical compositions thereof, and uses in the manufacture of a medicament for treating HCV infection or a HCV disorder thereof.Type: GrantFiled: November 28, 2013Date of Patent: October 31, 2017Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Yingjun Zhang, Jiancun Zhang, Hongming Xie, Qingyun Ren, Shifeng Li, Changping Fu, Bailin Hu, Xiwei Wu, Changhua Tang
-
Patent number: 9771619Abstract: An miRNA expression signature comprising a set of one or more miRNAs associated with metastatic cancer is provided. In one embodiment, the expression signature is selected from the group consisting of miR-10b, miR-139-5p, miR-130b and miR-199b-5p. In some aspects, miR-199b-5p and miR-130b are overexpressed in metastatic cancer; and miR-10b and miR-139-5p are downregulated in metastatic cancer. Such an expression signature may be used in methods for predicting metastasis, risk for developing metastasis or a prognosis in a cancer. In another embodiment, a method for establishing such a cancer miRNA expression signature is provided.Type: GrantFiled: October 28, 2011Date of Patent: September 26, 2017Assignee: CITY OF HOPEInventors: Huiqing Wu, Xiwei Wu
-
Publication number: 20170022570Abstract: The current disclosure provides, inter alia, method of determining benign nodules from thyroid cancer in a subject that is found to have a thyroid nodule, method of treating thyroid cancer in a subject detected to have thyroid cancer by the method of the current disclosure, compositions for determining benign nodules from thyroid cancer in a subject, and kits including reagents and composition for determining benign nodules from thyroid cancer in a subject.Type: ApplicationFiled: July 22, 2016Publication date: January 26, 2017Inventors: MARIA A. HAHN, John H. Yim, Yuman Fong, Arthur X. Li, Xiwei Wu
-
Patent number: 9416139Abstract: A compound of formula (I) or a stereoisomer, a geometric isomer. a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder.Type: GrantFiled: November 28, 2013Date of Patent: August 16, 2016Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Jiancun Zhang, Yingjun Zhang, Hongming Xie, Qingyun Ren, Bailin Hu, Changping Fu, Xiwei Wu, Shifeng Li, Chenglin Wang, Zhikeng Zhang
-
Publication number: 20150307509Abstract: Provided are fused tricyclic compounds effective to inhibit the function of the NS5A protein of formula (I), wherein X, X?, Y, Y?, A, A?, Q1, Q2, R1-R4, X4, R5a, f and W are defined as in the description. Also provided herein are pharmaceutical compositions thereof, and uses in the manufacture of a medicament for treating HCV infection or a HCV disorder thereof.Type: ApplicationFiled: November 28, 2013Publication date: October 29, 2015Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Yingjun ZHANG, Jiancun ZHANG, Hongming XIE, Qingyun REN, Shifeng LI, Changping FU, Bailin HU, Xiwei WU, Changhua TANG
-
Publication number: 20150299215Abstract: A compound of formula (I) or a stereoisomer, a geometric isomer. a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder.Type: ApplicationFiled: November 28, 2013Publication date: October 22, 2015Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Jiancun Zhang, Yingjun Zhang, Hongming Xie, Qingyun Ren, Bailin Hu, Changping Fu, Xiwei Wu, Shifeng Li, Chenglin Wang, Zhikeng Zhang
-
Publication number: 20150232509Abstract: A compound of formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder.Type: ApplicationFiled: September 29, 2013Publication date: August 20, 2015Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Yingjun Zhang, Jiancun Zhang, Hongming Xie, Qingyun Ren, Xiwei Wu, Huichao Luo, Changping Fu, Bailin Hu, Shifeng Li, Changhua Tang, Yong Lei, Quanxing Yu, Qinghong Fang, Chenglin Wang
-
Publication number: 20140274769Abstract: Provided are methods of treating breast cancer in a subject in need thereof comprising administering to the subject an effective amount of an inhibitor of miR-105 or an inhibitor of miR-122 are provided. Also provided herein are methods of determining a level of miR-105 or a level of miR-122 in a subject that has or is at risk for developing breast cancer. The method includes obtaining a biological sample from the subject and determining a level of miR-105 or a level of miR-122 or a combination thereof in the biological sample, wherein a higher level of miR-105 or miR-122 as compared to a control indicates that the subject has or is at risk of developing breast cancer.Type: ApplicationFiled: March 10, 2014Publication date: September 18, 2014Applicant: City of HopeInventors: Shizhen Emily Wang, Xiwei WU, Miranda Y. Fong
-
Patent number: 8399193Abstract: The present invention relates to the identification of novel DNA biomarkers and the use of the aberrant methylation patterns of the biomarkers to diagnose a disease or a condition (e.g., a cancer) associated therewith. In particular, the present invention relates to the use of the novel DNA biomarkers to diagnose lung cancers, e.g., squamous cell carcinomas and adenocarcinomas.Type: GrantFiled: August 29, 2008Date of Patent: March 19, 2013Assignee: City of HopeInventors: Gerd P. Pfeifer, Tibor A. Rauch, Zunde Wang, Xiwei Wu
-
Publication number: 20120108446Abstract: An miRNA expression signature comprising a set of one or more miRNAs associated with metastatic cancer is provided. In one embodiment, the expression signature is selected from the group consisting of miR-10b, miR-139-5p, miR-130b and miR-199b-5p. In some aspects, miR-199b-5p and miR-130b are overexpressed in metastatic cancer; and miR-10b and miR-139-5p are downregulated in metastatic cancer. Such an expression signature may be used in methods for predicting metastasis, risk for developing metastasis or a prognosis in a cancer. In another embodiment, a method for establishing such a cancer miRNA expression signature is provided.Type: ApplicationFiled: October 28, 2011Publication date: May 3, 2012Inventors: Huiqing Wu, Xiwei Wu
-
Publication number: 20110301050Abstract: One aspect of the present disclosure relates to a composition comprising a DNA hypermethylation brain cancer marker on acellular DNA of a human subject. DNA hypermethylation brain cancer markers (or DNA hypermethylation markers) are frequently methylated in the DNA of brain cells and acellular DNA of individuals suffering from brain cancer. These DNA hypermethylation markers are not frequently methylated in the DNA of brain cells and acellular DNA of individuals who do not suffer from brain cancer. Another aspect of the present disclosure relates to a method of diagnosing brain cancer in a human subject comprising providing a sample containing acellular DNA from the human subject, determining whether one or more DNA hypermethylation markers on the acellular DNA are hypermethylated, and diagnosing brain cancer when the DNA hypermethylation markers are hypermethylated.Type: ApplicationFiled: March 22, 2011Publication date: December 8, 2011Inventors: GERD P. PFEIFER, XIWEI WU, TIBOR A. RAUCH
-
Publication number: 20090305256Abstract: The present invention relates to the identification of novel DNA biomarkers and the use of the aberrant methylation patterns of the biomarkers to diagnose a disease or a condition (e.g., a cancer) associated therewith. In particular, the present invention relates to the use of the novel DNA biomarkers to diagnose lung cancers, e.g., squamous cell carcinomas and adenocarcinomas.Type: ApplicationFiled: August 29, 2008Publication date: December 10, 2009Inventors: Gerd P. Pfeifer, Tibor A. Rauch, Zunde Wang, Xiwei Wu